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1 INTRODUCTION AND OBJECTIVE OF THE STUDY 
1.1 Insulin resistance and human placenta in Gestational diabetes 
Gestational diabetes mellitus (GDM) is a carbohydrate intolerance of varying degrees of severity 
with onset or first recognition during pregnancy. It is one of the most frequent metabolic 
disorders of pregnancy affecting 1-10% of all pregnancies. Usually it disappears when pregnancy 
is over. Women who had GDM are at higher risk of developing diabetes, mainly type 2 Diabetes 
at a later stage in their life1. In parallel with obesity epidemic the incidence of gestational 
diabetes mellitus has doubled in last year’s. 
There is certain confusion in terms and criteria. Currently, WHO suggests partial adoption of 
International Association of Diabetes and Pregnancy Study groups (IADPSG) criteria48. Thus, if 
a nonsymptomatic pregnant women meets diagnostic criteria of diabetes during pregnancy it is 
diabetes in pregnancy (IAPDSG uses term “overt diabetes”). Gestational diabetes is diagnosed at 
any time in pregnancy according to IADPSG criteria: 
Fasting plasma glucose: 5.1-6.9 mmol/l (92-125 mg/dl) 
1 h post 75g oral glucose load: ≥ 10.0mmol/l (180 mg/dl) 
2-h post 75g oral glucose load: 8.5-11.0mmol/l (153-199 mg/dl) 
After previous acceptance of IADPSG approach to screening and diagnosis of gestational 
diabetes, current ADA guidelines suggest alternative(either/or) two-step approach with 50g 
glucose load in nonfasting individual with consequent measurement of BG after 60 minutes: if 
that is >7.8mmol/l (140mg/dl), a 100g OGTT should be performed and interpreted either et 
Carpenter-Coustan or National Diabetes Data Group. The two step approach has not been widely 
used in Europe. 
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Screening for GDM is generally undertaken in 24-28 week. 
Women with risk factors such as glycosuria, age more than 30 year, family history of diabetes, 
previous GDM or glucose intolerance, previous adverse pregnancy outcomes, or high risk 
ethnicity, may be tested for GDM earlier by oral glucose tolerance test (OGTT) and if negative, 
re-tested at 26-28 weeks of gestation. 
After the pregnancy ends, the woman should be re-classified as having either diabetes mellitus, 
or IGT, or normal glucose tolerance based on the results of a 75 g OGTT six weeks or more after 
delivery. It should be emphasized that such women, regardless of the 6-week post-pregnancy 
result, are at increased risk of subsequently developing diabetes. The significance of IFG in 
pregnancy remains to be established. Any woman with IFG, however, should have a 75 g OGTT. 
Recent evidence indicates a worrisome rise in the prevalence of gestational diabetes that is 
largely explained by the increase in maternal obesity. The efforts to reverse this trend are critical 
and great evidence support the use of screening and treatment for women at risk. 
Diabetes in pregnancy is associated with a number of adverse outcomes including birth trauma, 
neonatal hypoglycaemia, macrosomia and pre-eclampsia.  
There are well-recognized associations between gestational diabetes and increased risks of 
fetalmacrosomia, birth trauma, and cesarean delivery. 
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The management of GDM still attracts some controversy regarding the exact modality of 
treatment to be used: lifestyle changes, diet and adjusted doses of insulin, or the emerging trend 
of the use of oral hypoglycemic drugs. There is agreement on the benefits of treating GDM, as 
untreated gestational diabetes has been associated with significant risks of perinatal morbidity in 
all levels of disease severity, and treatment has been associated with reduced perinatal 
complications and maternal morbidity. 
The overall goal of diabetes management is to achieve as near normal physiological or ideal 
values as possible, without detriment to quality of life and, for glucose control in particular, 
without causing significant hypoglycemia. 
 
Nutritional management in diabetes aims to assist in optimising metabolic control and reducing 
risk factors for chronic complications, this includes the achievement of blood glucose and 
glycosilated hemoglobin (HbA1c) levels as close to normal as is safety possible and serum lipid 
concentration as well as blood pressure values that may be expected to decrease the risk for 
macrovascular diseases. Individual therapeutic needs and the quality of life of the person with 
diabetes have to be considered when nutritional objectives are defined. 
All women with GDM should receive nutritional counselling and be instructed in blood glucose 
self-monitoring. If blood glucose levels cannot be maintained in the normal range (fasting 
<95mg/dl and 1h after meals<140mg/dl) insulin therapy should be initiated. 
 
Monitoring diabetes 
Glycemic control should be monitored regularly for all patients with diabetes. The optimal 
method of determining risk of long-term complications is through HbA1c measurement and 
series of blood glucose measurements. Women with GDM should monitor the level of glycemia 
every day two hours after breakfast and at least one time per week before lunch.  
When medical nutrition therapy is not successful in maintaining target glucose values during 
pregnancy complicated by GDM, medication is required. Insulin has been the 
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traditional treatment under such circumstances. The use of oral antidiabetic medications in the 
management of gestational diabetes has increased over the past several years. 
Maternal and fetal monitoring is required in order to minimise maternal and fetal/neonatal 
morbidity and perinatal mortality.  
 It is of great importance understanding the relationships between glucose intolerance and 
pregnancy risk. For that reason even women with fasting hyperglycemia in pregnancy are at 
increased risk for fetal death. For that reason changes in recommendation criteria for GDM have 
resulted in the diagnoses of gestational diabetes in an increasing number of women who were 
previously normal. 
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Gestational diabetes results from insulin resistance and inadequate compensatory insulin 
secretion. Even in normal pregnancy, in the middle of the second trimester progressing to the 
third trimester, it is present physiological insulin resistance that result from increased maternal 
adiposity and hormones made by the placenta2.  The human placenta expresses all known 
cytokines which are also produced in adipose cells, like TNF α, leptin and resistin3.  
 Whether placenta at term is able to synthesize adiponectin is still in debate. These placenta 
cytokines contributes to low grade inflammation, developing during the third trimester of 
pregnancy3.  Inflammatory cytokine TNF α, which is produced from adypocites, placenta, T 
cells, monocites, macrophagy, neutrophils and fibroblasts together with adiponectin from 
adypocites are active mediator in inducing insulin resistance during pregnancy2. First, it is 
described that TNF α impairs insulin signalling by diminishing insulin receptor (IR) tyrosine 
kinase activity2. Studies in pregnancy have reported that changes in insulin sensitivity from early 
(22-24 weeks) to late (34-36 weeks) gestation correlate with plasma TNF- α 4. Second, TNF α 
suppress transcription factor peroxisome proliferator-activated receptor (PPAR)-γ and inhibit 
lipid cell differentiation, and lipid storage favouring increased lypolisis. This transition to insulin 
resistance contributes to greater postprandial increases in FFAs and increased hepatic glucose 
output that result in greater fuel availability to the fetus2,4. And, third TNFα and other 
proinflamatory mediators suppress the transcription of adiponectin in adypocite5,6 contributing to 
insulin resistance.  
In the other site, placental hormones like Human Placental Lactogen (hPL) and human placental 
growth hormone (hPGH), which are increased up to 10 fold during pregnancy, prevent insulin 
signalling downstream in skeletal muscle enhancing insulin resistance2. It is also shown that 
placenta growth hormone in the same way like TNFα; accelerate transition from lipogenesis to 
lypolisis by suppressing PPAR- γ2.  All these metabolic changes are required to direct maternal 
nutritients toward fetoplacental unit allowing adequate fetal growth.  
Leptin is cytokine secreted from the synciciotrophoblast of the placenta so during the first 
trimester of pregnancy its level rise and decline back to normal after delivery7.  Increased level 
of leptin in maternal blood during pregnancy is caused by placental production and as well from 
adipose tissue2,7. Stimulation of leptin production is favorised by human Chorionic Gonadotropin 
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(hCG) and vice versa8. Insulin is another hormone that is involved in regulation of secretion of 
placenta leptin. There are number of insulin receptors found in the placenta with primary 
localisation during the beginning of gestation in syncytiothrophoblast and by the term of 
gestation in the endothelium2.  In report from author Lappas it is indicated that leptin activate the 
release of proinflammatory cytokines and prostaglandins from human placenta, reflecting 
inflammatory, immunological and vascular response7,9. All these changes are in line with 
modifications of placental morphology with increased parenchyma tissue cellullarity and 
enhanced fetoplacental angiogenesis10.  
Adiponectin is one of the adipokines released from adipose tissue which is exclusively 
synthesized in adipocytes and has insulin sensitising, anti-inflammatory and antiatherogenic 
properties11.  With progression of obesity and insulin resistance, expression of adiponectin in fat 
and in plasma decrease12.  It is shown that adiponectin secretion in white adipose tissue decline 
with advancing gestation, even in lean women13,  suggesting that there are pregnancy related 
factors that reduce adiponectin levels. 
In diabetic environment, cytokines and inflammation related genes in adipose tissue and in 
placenta are over expressed10.  In the study of Tatjana Radaelli10 it is shown that one third of the 
placental genes are modified during GDM reflecting a state of chronic inflammation with signs 
of vascular dysfunction. Over expression of TNFα in GDM is associated with increased fetal 
adiposity2,10. There are other mediators that are upregullated in GDM like interleukin (IL)-6 and 
leptin14.  All together they enhance insulin resistance. In addition adiponectin may be implicated 
in the loss of insulin sensitivity in pregnancy with GDM through a decrease in maternal 
concentration.  
  In women with GDM insulin resistance is more severe and leads to increase concentration of 
glucose and other nutritients such as lipids and amino acids in the maternal blood, increasing 
their transfer to the fetus15.  Therefore different metabolic perturbations in the maternal 
environment are transmitted across the placenta which plays a central role in fetal programming 
regulating fetalnutritients supply and fetal growth 16.  
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With the growing prevalence of obesity, scientific interest in the biology of adipose tissue has 
been extended to the secretory products of adypocites, since they are increasingly shown to 
affect several aspects in the pathogenesis of obesity related diseases. In the last decade adipose 
tissue has been added to the panel of endocrine organs20. 
In recent years, a number of additional signalling molecules secreted by adipose tissue have been 
discovered, commonly referred to as “adypocitokines”. Among these, adiponectin is perhaps the 
most interesting and promising compound for the clinician since it has profound protective 
actions in the pathogenesis of diabetes and cardiovascular diseases. Adiponectin was found to be 
low in obese subjects and particular in insulin resistant patients20 
It is well acknowledged that the sequel of obesity, particularly diabetes and cardiovascular 
disease, are influenced to a great extent by the actions of these adipocytokines49. Thereby, 
adipose tissue directly contributes to the pathogenesis of obesity related disorders. 
1.2  Fetal development in inflammatory milieu 
Altered metabolic environment in GDM mother expose the fetus to high level of glucose during 
critical windows of development that may result in changes of the biology of adypocites and 
result in increased fat mass in infants17.  It is suggested that adverse influences during fetal life 
can alter the structure and function of distinct cells and organ systems thereby „programming“ 
the individual for an increased risk of developing disease in adult life16. Increased glucose 
transfer from mother with GDM to the fetus results in β cell hyperplasia, increased insulin 
secretion and greater fetal adiposity18. 
Leptin plays an important role in fetal growth and metabolism, in thermo genesis, 
haematopoesis, regulate puberty onset and reproduction19,20. It is mainly produced in white 
adipose tissue (WAT) but it is evident in other tissue like in placenta, brown adipose tissue 
(BAT) skeletal muscle, pituitary, ovaries, liver and gastric epithelium21.Fetal plasma leptin is 
derived from placenta in early gestation, in week 7-14 up to term and from adipose tissue which 
start to develop from 14 weeks of gestation22. During development of fetus in utero the level of 
leptin increases and it is shown that it correlate positively with birth weight and neonatal 
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adiposity23.  This fact is also explained in the study of Linnemann22 where in growth retarded 
fetus concentration of leptin was lower.  There are a number of factors in feto/maternal/placenta 
unit which are involved in leptin production like insulin, cortisol and hCG22.  Insulin plays a 
chronic role in the regulation of leptine gene expression and production by WAT. In cases of 
hyperinsulinemia plasma concentration and gene expression in WAT is increased21.  This role of 
insulin in leptin production is seen in diabetic pregnancies and also in large for gestational age 
(LGA) infants where leptin levels are over expressed. Steroids also cause threefold increase in 
level of leptin and that was evident in preterm infants when the mother have taken 
corticosteroids and additionally this fact explain involvement of leptin in pulmonary 
development in utero24. During pregnancy almost all hCG is released in maternal circulation and 
cause increased release of leptin from adipose tissue22. Leptin have important role in 
osteogenesis and that is explained with high level of receptors and high level of its expression in 
cartilage and bone development22. It is described gender differences in leptin level, with lower 
concentration in males than in females and this  explain negative correlation that exist between 
leptin and testosterone25.  Finally, the process of transition from fetus to neonate represents one 
of the major physiological, hormonal and environmental challenges. To survive the fetus must be 
prepared to termorregullate and feed independently shortly after birth. In this process Leptin 
together with cortisol, thyroid hormones and sympathetic nervous system plays important role in 
initiating breathing and thermoregulation at birth19.  
Another important role of leptin is that it acts as an afferent satiety signal in the hypothalamus, 
suppressing food intake and stimulating energy expenditure26.  After birth in healthy neonate’s 
leptin level decline dramatically and this mechanism may be important for the stimulation of 
feeding behaviour. But, it is suggested that elevated level of insulin and leptin during “critical 
periods” of fetal development in different animal models leads to a  perinatally acquired 
“malorgansiation” of orexigenic and anorexigenic neurons in hypothalamic arcuate nucleus that 
might contribute to the occurrence of hyperphagia, overweight and hyperinsulinemia throughout 
later life27.  
A number of studies have provided evidence that leptin is involved in the pathogenesis of 
atherosclerotic vascular diseases, proliferation of cancer cells, and stimulate bone formation. 
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Adiponectin is another adypocitokine, which influence insulin sensitivity and increase fatty acid 
oxidation in muscle. The most coherent and important effects to date have been shown for 
adiponectin, which renders it the most promising adypocitokine with the potential impact for the 
development of therapeutic strategies. 
Contrary to leptin, adiponectin, the protective factor, is decreased in obesity and has protective 
actions by ameliorating insulin resistance, and inhibiting atherosclerosis and possible even 
cancer growth. 
Hormones like insulin and glucocorticoids and, proinflammatory cytokines like TNF and IL-6 
downregullate adiponectin expression in adypocite. And in the other site PPAR γ increases its 
expression28. In GDM mother the level of adponectin is decreased compared with normal 
pregnancies and this fact can be an early event in the natural history of type 2 diabetes11.  In the 
study of Pardo Ines et al. adiponectin concentration in cord blood have shown positive 
correlation with birth weight, birth length, gestational age and leptin, indicating that adiponectin 
is synthesised in fetal tissue29.  In some other  studies it is shown that high adiponectin levels did 
not correlate with birth weight, but have only positive correlation with gestational age30,31,32. 
  Compared with adults, level of adiponectin in umbilical samples from newborns are higher, and 
this suggest its multiple role in tissue differentiation and growth during fetal intrauterine 
development30,29. In fetuses of GDM mother’s level of adiponectin are significantly lower 
compared to normal fetuses off the same gestational age30.  Low adiponectin serum 
concentration at baseline independently may predict the future risk for developing obesity and 
obesity related disorder12.  In the recent study of Jennifer Dyer33 it is shown that LGA neonates 
born to mothers with GDM have decreased insulin sensitivity at birth, and this fact may reflect 
alterations in metabolic programming that could contribute to later development of metabolic 
syndrome or T2DM in childhood or adulthood. There are two studies, one in PIMA Indians34 and 
another recent  analyses of American youth35 that have linked LGA non IDM and LGA IDM 
neonates with later development of type 2 DM and metabolic syndrome.   
Taken together we can say that infant of a GDM mother may have a variable phenotype based on 
the interaction of genes and the in utero environment36.  GDM increases the risk of macrosomia, 
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infant with birth weight greater then 90th percentiles for gestational age and increase risk for 
perinatal complications and long-term risk for obesity and type 2 diabetes. While, normalising 
maternal glucose levels have reduced neonatal morbidity in GDM, the macrosomia rate still has 
remained elevated compared with the normal obstetrical population37. 
All women have to be instructed about their (sevenfold increased relative) risk of type 2 diabetes 
at follow-up and possibilities for diabetes prevention, in particular weight management and 
maintenance/increase of physical activity. Monitoring of the development of the offspring and 
recommendation of healthy lifestyle of the children and family is recommended. 
 
Recent data show that prevalence of gestational diabetes has increased in several race/ethnicity 
groups during the past 20 years38. Increasing GDM contribute to increasing diabetes and obesity 
in their offspring. This circulus vicious, as a public health concern require more inside in 
understanding metabolic changes in fetal environment that will help to address these problems in 
the next future. 
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2  HYPOTHESIS 
 
We expect that: 
• The concentration of leptin and insulin in offspring of GDM mothers will be increased 
proportionally with increased birth weight, but the level of adiponectin in LGA 
newborns from GDM mothers will be decreased compared with LGA newborns from 
normal healthy pregnancies. 
• The HDL cholesterol in LGA newborns from GDM mothers will be lower than in LGA 
newborns from normal pregnancies and will have positive correlation with adiponectin. 
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3  AIMS OF THE STUDY 
3.1  Main Aim of the Study 
1. The main aim of this study will be to determine a cause of enhanced fetal growth (>90 
percentile) in well-controlled (daily glucose profile in regular values and optimal HbA1c values) 
gestational diabetic pregnancies.  
3.2  Specific Aims 
1. To evaluate the concentration of adiponectin, leptin and C peptide in umbilical vein blood 
of newborns born from mother with gestational diabetes at different gestational age and 
to investigate their associations with fetal development. 
2. To measure adiponectin, leptin and insulin levels in maternal serum and umbilical cord 
serum at delivery and to examine whether or not there are correlations between those 
hormonal levels and neonatal birth weights, maternal body weights and body mass 
indexes. 
3. To examine the influence of gestational diabetes on cord lipids at birth and relationship to 
body composition, cord insulin, leptin and adiponectin 
4. To evaluate lipid metabolic profile in women with gestational diabetes and normal 
pregnancies. 
  
    
 
13 
 
4  MATERIALS AND METHODS 
4.1 Subjects 
This study was a cross sectional. Pregnant women admitted in Gynaecology Department „State 
Referral Centre for Diabetes in Pregnancy“in Zagreb have undergone routine physical 
examination and a 75 gr oral glucose tolerance test –OGTT. Blood samples were drawn at 
fasting and 120 min after glucose load. A diagnosis of GDM was defined by the WHO criteria of 
the following vein plasma glucose values: Fasting: ≥ 5.6 mmol/l   and 2 h: ≥ 7.8 mmol/l. 
A total of 37 GDM mothers were randomly selected with their healthy normal babies and 46 
healthy age-matched pregnant women were randomly selected with their newborn babies. 
Selected control women had no significant history of illness, no pregnancy related complications 
and no risk factor for gestational diabetes. They have normal glucose tolerance test in second and 
third trimester. 
Inclusion criteria: 
Signed informed consent 
Pregnant women diagnosed for GDM for the first time.  
Exclusion criteria: 
 Personal history of GDM and history of previous abnormal glucose tolerance test 
 Pregnancy related complications (hypertension, preeclampsia and eclampsia) 
Acute or chronic infections, and 
Current use of corticosteroids or other drugs  
Maternal characteristics included in the study were:  age, weight, height, BMI, parity, mode of 
delivery, and gestational age at delivery. Newborn characteristics included in the study were: 
gender, gestational age, head circumferences, weight, length and Ponderal index.  
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4.2  Methods 
Baseline evaluation 
On the day of the OGTT, demographic and historical information were collected by interviewer-
administered questionnaire. Data collection included: 1) patient demographics; 2) information 
regarding current pregnancy including illnesses, infections, and medications; 3) personal 
medical, obstetrical, and smoking history; and 4) family history. Specific GDM risk factors were 
assessed including age, weight before pregnancy, weight gain during pregnancy, personal history 
of GDM, history of previous abnormal glucose tolerance test, previous delivery of large for 
gestational age infant, and family history of GDM or type 2 DM.  
Analytical procedures - Biochemical measurements 
The 75g OGTT was performed between 20 - 28 weeks of gestation, in the morning after an 
overnight fast of at least 8 h and venous blood samples were drawn at baseline and 120 min 
following ingestion of a standard 75-gr glucose load.  
Blood samples were taken from mother before delivery and from neonates at the time of delivery 
from venous cord blood before separation of the placenta, and tested for concentrations of 
adiponectin, leptin, C-peptide, glucose, triglycerides (TG), total cholesterol (TCH), low density 
lipoprotein (LDL)-cholesterol  and high density lipoprotein (HDL)-cholesterol. Analyses of the 
blood samples were blind. Serum samples obtained by centrifugation were immediately frozen 
and stored at −70°C until further analysis. 
 Plasma triglycerides (TG) were measured by GPO-PAP method and total cholesterol by COD-
PAP method; High density lipoprotein (HDL)-cholesterol and low density lipoprotein (LDL)-
cholesterol were measured by cholesterol oxidase (CO) reaction method (DADE Behring, 
Dimension). Plasma glucose was determined by hexokinase glucose- 6-phosphate dehydrogenase 
method (Siemens DADE Behring, Dimension Xpand, clinical chemistry system).  
Serum adiponectin, leptin and C-peptid levels were measured by the ELISA method using the kit 
of Bio Vendor Laboratory Medicine - Hamburg. The low limit of adiponectin detection will be 
0.2µg/ml. and the intra and interassay coefficient of variation (CV) was 7.0% and 8.2% 
    
 
15 
 
respectively. The sensitivity of the leptin assay was 1.0 ng/ml and the intra and interassay CV 
was 5.95% and 11.55% respectively. The range of the C-peptide assay was between 0-16 ng/ml 
and the intra and interassay CV values 6.54% and 9.33% respectively.  
Anthropometry 
Anthropometric measurements of newborns were done immediately after delivery by 
paediatrician and included measurements of weight, height and head circumferences. 
Measurements of height and weight were obtained using a medical scale and gestational age was 
determined by paediatrician.  
Calculation 
Gestational age at delivery was calculated according to the last menstrual period and confirmed 
by ultrasound examination during the first trimester or early second trimester. Gestational 
diabetes was ruled out or confirmed by oral glucose tolerance test (OGTT) performed from 20-
28 week of gestation. Body mass index (BMI) was calculated as weight (kg) per height (m2). 
Ponderal Index at birth was calculated with the standard formula of weight (kg) divided by the 
cube of the length at birth (m3). Birth weight percentiles were calculated according to published 
standards. 
4.3  Statistical analysis 
Data were analyzed with descriptive statistics, and differences between groups were assessed 
with t-test for normally distributed numerical variables, or nonparametric test for two 
independent groups (Mann-Whitney test) in case of not normally distributed numerical variables. 
Normality was tested with Kolmogorov-Smirnov test. Qualitative variables were tested with Chi-
square statistics were possible, otherwise with two-way Fisher exact test. Spearman correlation 
test was used to compare not normally distributed variables and Pearson Correlation for normally 
distributed variables.  
The level of statistical significance is chosen to be 0.05. 
The SPSS version 17.0 was used to perform statistical analysis. 
Power calculation was made upon published results (30, 31, 40 and 41). Estimation based on 
mean value for diabetic group was 23.1 µg/l with standard deviation 3.5µg/l, and control mean 
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value 29.7 µg/l with standard deviation 4.4 µg/l. With the expectation of equal sample sizes per 
group, alpha error probability of 0.05 for power of 0.90, total sample size was estimated to 18.  
Sample size was increased with the expectation of possible exclusion from the study, and sample 
stratifications for further data analysis, to 40. 
4.4  Ethics 
The study was conducted according to all currently valid and applied guidelines whose purpose 
is to assure proper conduction and protection of persons included in this research as examinees, 
including the Basics of Good Clinical Practice and Helsinki Declaration, Health Protection Law 
of the Republic of Croatia (NN 121/03), and Patient’s Rights Law of the Republic of Croatia 
(NN 169/04). 
Identity of healthy examinees and patients remained confidential and protected. 
 
Consent form and subject information 
Prior to the beginning of the trial, the investigator presented oral and written information about 
the investigation. The investigator had to be ensured that subject were fully informed about the 
aim of the study, procedures, potential risks, discomforts, and expected benefits which could 
come out from these investigations. Also, subjects were informed and agreed that the Health 
Authority personnel would require the access to data. It was emphasized that participation would 
be voluntary and that subjects would have the right to withdraw from the trial at any time 
without prejudice. A freely given, written Informed Consent was obtained from all subject prior 
their allocation for the treatment in accordance with the study protocol. 
 
Ethics committee 
Prior to the start of the trial, all three documents-research design of the thesis project proposal, 
informed consent, and agreement letter for participation of subjects, were submitted to the  
Research Ethic Board at Gynaecology Department Hospital in Zagreb and of the school of 
medicine, University of Zagreb. A written approval for these documents was obtained. 
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5  Results 
A total of 37 pregnant women diagnosed for the first time with Gestational diabetes and their 
newborn babies participated in the study. As control subjects 46 healthy pregnant women and 
their newborn babies were selected. 
Baseline characteristics and metabolic parameters of pregnant women are presented in table 1-2. 
The differences between groups are assessed with t-test for normally distributed numerical 
variables, and nonparametric test for two independent groups (Mann-Whitney test) in case of not 
normally distributed numerical variables. 
Table 1. Patient characteristics 
characteristics GDM group Control group P-value 
Patients (n) 37 46   
Maternal age(yr) 32.6 ± 6.1 30.2 ± 4.8 P=0.042 
First trimester BMI (kg/m2) 29.6 ± 6.0 23.3 ± 4.3 P<0.0001 
Weight gain in pregnancy (kg) 13.2 ± 6.3 15.9 ± 5.0 P=0.033 
Fasting value: OGTT 5.6 ± 1.0 4.2 ± 0.4 P<0.0001 
1-Hour value: OGTT  10.5 ± 1.4 7.6 ± 1.4 P=0.017 
2-Hour value: OGTT  9.5 ± 1.4 5.7 ± 0.9 P<0.0001 
HbA1c(%) 5.9 ± 0.4 4.0 ± 0.2 P=0.045 
Values are given as mean ± SD; *T-test or U’- Mann Whitneytest. 
Gestational diabetic mothers had significantly higher BMI (first trimester) than a control group 
(29.6 ±6.0 vs. 23.3 ± 4.3, P<0.0001) and had a higher Haemoglobin A1c value at the time of the 
OGTT (5.9 % vs. 4.0%, P=0.045), but the weight gain in well controlled gestational diabetic 
pregnancy was lower compared with normal healthy pregnancies (13.2 ±6.3 vs.15.9 ±5.0, 
P<0.05). 
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Table 2 
 Parameter GDM group Control group P-value 
Serum c - peptide (pmol/L) 1038.8 ± 628.1 976.9 ± 1031.3 P=0.08 
Serum adiponectin (ng/mL)  10871.3 ± 5184.2 13418.9 ± 5148.6 P=0.021 
Serum Leptin (ng/mL) 209.5 ± 194.4 242.6 ± 231.5 P=0.604 
Serum Insulin (mU/L) 24.9 ± 23.7 22.7 ± 25.7 P=0.279 
Plasma glucose (mmol/L) 5.3 ± 1.4 4.7 ± 0.6 P=0.019 
HOMA - IR  5.5 ± 2.9 3.9 ± 1.8 P=0.002 
Cholesterol (mmol/L) 6.11 ± 1.24 5.00 ± 0.52 P<0.0001 
Tryglicerides (mmol/L) 3.80 ± 0.74 2.99 ± 0.58 P<0.0001 
HDL (mmol/L) 1.80 ± 0.31 1.91 ± 0.33 P=0.866 
LDL (mmol/L) 3.98 ± 0.66 2.93 ± 1.07 P<0.0001 
Values are given as mean ± SD.  
*T-test or U’- Mann Whitnney test . 
Serum adiponectin concentration were significantly lower in gestational diabetic mothers when 
compared with healthy control subjects (10871.3 ± 5184.2 vs. 13418.9 ± 5148.6, P=0.021).  The 
secretions of adiponectin in normal and complicated pregnancy with gestational diabetes suggest 
an involvement of adiponectin in insulin resistance during gestation. Concentration of glucose 
was significantly higher in GDM (5.3 ± 1.4 vs. 4.7±0.6, P<0.05) and HOMA –IR (5.5 ± 2.9 vs. 
3.9 ±1.8, P=0.002) than in control subjects. 
To assess the role of adiponectin in lipid metabolism it was tested lipid profile in GDM and 
control group. Cholesterol concentration was significantly higher in GDM (6.11 ± 1.24 vs. 5.00 
± 0.52, P<0.0001), triglycerides (3.80 ± 0.74 vs. 2.99 ± 0.58, P<0.0001) and LDL (3.98 ± 0.66 
vs. 2.93 ± 1.07, P<0.0001) compared with control subjects. 
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Spearman correlation test was used to assess how adiponectin level correlate with BMI and as 
aspected, adiponectin in maternal blood correlated inversely with BMI(r= -0.428, P=0.008).  
 
Correlation: r= -0.428, 95% Cl-0.666 to -0.111, P=0.008 
 
Figure 1.Correlation between adiponectin concentration in maternal blood and maternal body 
mass index-BMI 
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Baseline characteristics and metabolic parameters in newborns of gestational diabetic mothers 
and newborns of normal healthy pregnancy are shown in table 3-4. 
Table 3. 
Characteristics  GDM group Control group P-value 
n 37 46   
Gestational age (weeks) 39.4 ± 1.6 39.4 ± 1.0 P=0.719 
Body weight (g) 3644.1 ± 765.1 3513.0 ± 597.4 P<0.0001 
Body length (cm) 50.8 ± 2.7 50.2 ± 2.8 P=0.921 
Apgar score 1’ 9.2 ± 1.6 9.5 ± 1.1 P=0.584 
Apgar score 5’ 9.7 ± 0.6 10.1 ± 1.5 P=0.403 
HOMA- fetal IR 1.4 ± 0.9 0.6 ± 0.4 P<0.0001 
Ph_umbilical 7.2 ± 0.1 7.2 ± 0.1 P=0.853 
Values are given as mean ± SD.  
*T-test or U’- Mann whitnney test . 
Offspring’s of GDM were born almost in the same gestational weeks as a control group but the 
weight was significantly higher in GDM (3644.1 ± 765.1 vs. 35130 ± 597.4, P<0.0001) and 
Insulin resistance HOMA-IR was significantly higher in offspring of GDM (1.4 ±0.9 vs. 0.6 
±0.4, P<0.0001). 
The Apgar scores of the study and control patients were comparable and satisfactory. 
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Table 4. 
 Parameters GDM group Control group P-value 
n 37 46   
Cord c-peptid ( pmol/L) 478.0 ± 285.3 282.3 ± 108.9 P=0.0002 
Cord Adiponectin (ng/ml) 32136.6 ± 11103.5 39842.3 ± 8105.2 P=0.0016 
Cord Leptin (ng/ml) 104.0 ± 106.3 71.8 ± 98.8 P=0.034 
Cord Insulin (mU/L) 11.5 ± 12.4 4.4 ± 3.1 P<0.0001 
Cord glycose (mmol/L) 3.8 ± 0.7 3.0 ± 0.7 P<0.0001 
Cord cholesterol (mmol/L) 1.86 ± 0.37 1.72 ± 0.29 P=0.042 
Cordtriglycerides (mmol/L) 0.37 ± 0.22 0.28 ± 0.09 P=0.026 
Cord HDL (mmol/L) 0.59 ± 0.15 0.70 ± 0.17 P=0.0026 
Cord LDL (mmol/L) 1.01 ± 0.28 0.74 ± 0.15 P<0.0001 
Values are given as mean ± SD.  
*T-test or U’- Mann whitnney test . 
As shown in table 4, concentration of c- peptide (478.0 ± 285.3 vs. 282.3 ± 108.9, P=0.0002), 
insulin (11.5 ± 12.4 vs. 4.4 ± 3.1, P<0.0001) and leptin (104.0±106.3 vs. 71.8 ± 98.8,P=0.034) in 
umbilical cord blood of offspring of GDM, were significantly higher compared with normal 
subjects and only adiponectin concentration was significantly lower(32136.6 ±11103.5 vs. 
39842.3 ±8105.2, P=0.0016). 
Lipid profile also shows significantly disturbances in newborns of GDM with higher 
concentration of cholesterol (1.86 ±0.37 vs. 1.72 ±0.29, P=0.042), triglycerides (0.37±0.22 vs. 
0.28 ±0.09, P=0.026) and LDL (1.01 ± 0.28 vs. 0.74 ±0.15, P=<0.0001) and lower HDL 
(0.59±0.15 vs. 0.70 ±0.17, P=0.0026) compared with newborns of normal healthy pregnancies. 
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On Spearman correlation analysis, maternal adiponectin correlated inversely with neonatal birth 
weight and maternal leptin correlated positively with neonatal birth weight but not statistically 
significant. 
Correlation: r= -0.203, 95% Cl 0.502-0.139, P=0.228 
 
 
Figure 2.Correlation between maternal adiponectin concentration and birth weight in newborns 
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Correlation: r=0.0169, P=0.907 
 
Figure 3.Correlation between maternal leptin concentration and birth weight in newborns 
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T-test was performed to assess lipid profile in offspring of GDM and control group based on 
neonatal growth percentiles, table 5-6. 
Table 5.HDL (High density lipoprotein) cholesterol in umbilical cord blood in SGA, AGA and 
LGA newborns  
 
SGA-small for gestational age, AGA-appropriate for gestational age, LGA-large for gestational age 
  
Study group Data GDM group Control group P-value 
          
SGA 
(<10th percentiles) 
n 1 2 
  Mean ± SD 0.93 ± 0.0 0.68 ± 0.17 
          
AGA 
(10-90th percentiles) 
n 26 39 
0.0002 
Mean ± SD 0.58 ± 0.14 0.73 ± 0.16 
          
LGA 
(>90th  percentiles) 
n 10 5 
0.043 Mean ± SD 0.49 ± 0.14 0.68 ± 0.19 
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Table 6.LDL (low density lipoprotein) cholesterol in umbilical cord blood in SGA, AGA and 
LGA newborns  
Study group Data GDM group Control group P-value 
          
SGA 
(<10th percentiles 
n 1 2 
  Mean ± SD 0.78 ± 0.0 0.85 ± 0.09 
      
AGA 
(10-90th percentiles) 
n 26 39 
<0.0001 
Mean ± SD 0.97 ± 0.26 0.71 ± 0.13 
      
LGA 
(>90th  percentiles) 
n 10 5 
0.023 
Mean ± SD 1.32 ± 0.36 0.85 ± 0.26 
SGA-small for gestational age, AGA-apropriate for gestational age, LGA-large for gestational age 
 
Not only LGA neonates but also AGA neonates of GDM have significantly lower HDL (0.58 ± 
0.14 vs. 0.73 ± 0.16, P=0.0002)) and higher LDL (0.97 ± 0.26 vs. 0.71 ± 0.13, P= <0.0001) 
compared with neonates of healthy control group. 
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Cord blood adiponectin concentration in LGA newborns of GDM shows significantly lower 
concentration compared with AGA newborns (24469.0± 10478.8 vs. 34871.4 ± 10269.7, 
P=0.01).Cord blood leptin and insulin concentration did not show any statistical significance 
between two groups. 
Table 7. Concentration of cord blood adiponectin, leptin and insulin in AGA and LGA newborns 
of GDM  
  
AGA 
(10-90th percentiles) 
LGA 
(>90th  percentiles) 
P-value n 26 10 
Cord 
Adiponectin(ng/ml) 34871.4 ± 10269.7 24469.0 ± 10478.8 P=0.01 
Cord Leptin (ng/ml) 102.6 ± 111.8 113.6 ± 100.1 P=0.787 
Cord Insulin(mU/L) 11.3 ± 14.1 12.9 ± 6.4 P=0.787 
*T-test. 
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As aspected, concentration of insulin and C –peptide in umbilical cord blood correlated 
positively with neonatal birth weight. Concentration of leptin in umbilical cord blood also 
correlated positively with birth weight but not significantly (r=0.257, 95% CI,- 0.0824 to 0.544, 
P=0.124) and concentration of adiponectin correlated inversely with birth weight but not 
significantly(r= - 0.213, 95% CI,-0.51 to 0.128, P=0.203). 
 
Correlation: r=0.351, 95% CI (0.021-0.612), P=0.033 
 
Figure 4.Correlation between concentrations of cord c- peptide and birth weight in newborns 
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Correlation: r=0.363, 95% CI (0.0351-0.621), P=0.0269 
 
Figure 5. Correlation between concentrations of cord insulin and birth weight in newborns 
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Adiponectin concentration in umbilical cord blood of newborns of GDM was significantly 
inversely correlated with neonatal percentiles, respectively z-score (r= - 0.383, P=0.0192). 
 
 
Correlation: r= - 0.383, 95% CI (- 0.635 to -0.057), P=0.0192 
 
Figure 6. Correlation between concentrations of cord adiponectin and neonatal z-score 
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Insulin concentration in umbilical cord blood of newborns of GDM was significantly positively 
correlated with neonatal percentiles, respectively z-score (r= 0.384, P=0.0187) 
 
Correlation: r= 0.384, 95% CI (0.059 to 0.636),P=0.0187 
 
Figure 7. Correlation between cord insulin and neonatal z-score 
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Spearman rank Correlation was used to assess correlation of adiponectin with HDL, and as 
aspected umbilical cord adiponectin was positively correlated with HDL (r=0.325,P=0.0068). 
 
Correlations: r=0.325, 95% CI (0.087 to 0.528, P=0.0068) 
 
Figure 8. Correlation between concentrations of cord adiponectin and HDL 
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Concentration of adiponectin (24469.0 ± 10478.8 vs. 45359.6 ± 7592, P=0.0017) is significantly 
lower in LGA newborns of GDM mothers compared with LGA newborns of healthy control. 
Table 8. 
adiponectin 
GDM group Control group P - value 
n Mean ± SD n Mean ± SD 
 
AGA 26 34871.4 ± 10269.7 39 38791.3 ± 7992.6 P=0.089 
LGA 10 24469.0 ± 10478.8 5 45359.6 ± 7592.0 P=0.0017 
T -test  
 
Concentration of Leptin (102.6 ±111.8 vs. 62.0 ±94.4, P=0.039) in umbilical cord is significantly 
higher in AGA newborns of GDM mothers compared with AGA newborns of healthy control. 
Table 9. 
leptin 
GDM group Control group 
P - value n Mean ± SD n Mean ± SD 
AGA 26 102.6 ± 111.8 39.0 62.0 ± 94.4 P=0.039 
LGA 10 113.6 ± 100.1 5.0 127.2 ± 110.5 P=0.813 
Man Whitney test , T-test 
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Concentration of Insulin is significantly higher in AGA (11.3±14.1 vs.4.3 ±3.2, P<0.0001) and 
LGA (12.9 ±6.4 vs. 5.8 ±2.9, P=0.035) newborn of GDM mothers compared with AGA and LGA 
newborns of healthy control. 
Table 10. 
insulin 
GDM group Control group 
P - value n Mean ± SD n Mean ± SD 
AGA 26 11.3 ± 14.1 39.0 4.3 ± 3.2 P<0.0001 
LGA 10 12.9 ± 6.4 5.0 5.8 ± 2.9 P=0.035 
T-test 
 
Pearson Correlation test was used to compare correlation between maternal Adiponectin and 
HDL cholesterol in LGA newborns of GDM mothers(r= 0.05, 95% CI -0.57 to 0.65, P=0.88)but 
we did not find any correlation. 
Figure: 11 
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6  Discussions: 
 
To our knowledge, this study is the first cross sectional study planned to determine a cause of 
enhanced fetal growth (>90 percentile) in well controlled gestational diabetic pregnancies (ondiet 
only) and to evaluate the level of adiponectin and its role in lipid profile in LGA newborns from 
GDM.  
We achieved significant changes in metabolic parameters between newborns of GDM mothers 
and normal healthy pregnancies.  
First, weight gain in offspring of GDM was significantly higher compared with offspring of 
normal healthy pregnancies, increased maternal BMI and increased level of serum lipids and 
triglycerides were the strongest predictor of fetal macrosomia in our study.  
Women with GDM diagnosed for the first time during pregnancy have significantly higher BMI. 
Our study have shown that even in well controlled GDM mothers we find significant metabolic 
changes in lipid profile, increased concentration of cholesterol, triglycerides and LDL 
cholesterol. These changes in lipid profile can be attributed to the level of adiponectin which is 
significantly lower in GDM mothers compared with normal healthy control, upholding the 
importance of adiponectin in pregnancy induced insulin resistance. 
Adiponectin as an adipokine is recognised in many studies as a key regulator of insulin 
sensitivity and inflammation. In our study adiponectin concentration in GDM mothers inversely 
correlated with BMI.In addition, significant increased of glucose and Insulin resistance in 
maternal blood of GDM mothers predispose the fetus to develop in inflammatory environment.  
Diet control GDM mothers have significantly lower weight gain during pregnancy but this 
intervention seems to be not sufficient to prevent altered metabolic milieu during pregnancy.  
So, there is no doubt that maternal glycaemia and BMI in women with GDM are involved in 
determining birth weight of newborns. 
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Leptin is and adipokine secreted by several tissue into the circulatory system. There are 
contradictory results about the level of leptin in GDM mothers. Leptin levels have been 
reported either elevated 
39,40
 or reduced 
42
 or unaltered 
32
. In our study leptin level was lower in 
GDM mothers compared with healthy controlled subjects, and this might be explained that 
plasma leptin are markedly lowered by dieting. 
Adipocytokines secreted by adipose tissue are required for a number of physiological and 
metabolic processes39. Despite their potential importance as mediators in metabolic disorders, 
very little is known about their implications in GDM and in offspring of GDM mothers. There 
are some controversial thoughts about adipocytokines concentration in cord blood of offspring 
from GDM mothers. In recent study of Ategboet al40, it is shown that the level of leptin and 
adiponectin in LGA infants of gestational diabetic mothers were lower than in their age matched 
control newborns. In opposite the study of Jennifer Shine Dyer33 shows that leptin level was 
higher in LGA newborns and no changes in adiponectin, whereas study of Louise Pircet al41, did 
not find any differences in cord blood serum leptin, but adiponectin level was lower between 
those two groups. In our study, the level of adiponectin was significantly lower in LGA 
newborns of GDM because of higher fat mass. In the other site, leptin was slightly lower in LGA 
of GDM compared with LGA of control subjects with no statistical significance that might be 
due to a small sample size of LGA babies. Insulin concentration was significantly higher in AGA 
and LGA newborns of GDM compared to newborns of normal healthy pregnancies. 
 
The exact role of adiponectin in regulating intrauterine fetal growth has not been fully 
elucidated. Adiponectin hypersecretion observed in neonates may suggest a multiple role for 
adiponectin in tissue differentiation and growth during fetal development. Adiponectin has a 
great role in development of metabolic syndrome, which is further supportted by the close 
correlations of adiponectin with risk factors and components of the metabolic syndrome, such as 
insulin resistance, hyperinsulinemia, triglycerides and low density lipoprotein cholesterol, all 
uniformly reported in a variety of studies. Association between adiponectin and blood lipids have 
been demonstrated in adults and adolescents11,12, but limited data have been published on blood 
lipids in offspring of gestational diabetic mothers and their relation to adiponectin43,44.  It is 
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known that adiponectin may modulate the plasma lipid profile in an antiatherogenic manner, as 
associations with high cholesterol have been shown in adults45. In our study the mean level of 
serum adiponectin in offspring of GDM was significantly lower than in offspring of healthy 
control subjects. In addition, LGA newborns of GDM have significantly lower adiponectin levels 
than AGA newborns of GDM. One possible explanation for these findings can be that adipose 
tissue exerts its negative feedback mechanism and the correlation with birth weight is disrupted 
(46). So, when the quantity of adipose tissue is abnormally higher, like in LGA newborns, the 
negative feedbacks intensify to a degree that depresses the level of adiponectin46. Several lines of 
evidence indicate that an increase in fat mass leads to a down-rregullation of adiponectin.LGA 
newborns have not only excessive amount of adipose tissue, but also larger adypocites47.  
Therefore, both the large number and size of adypocites in LGA newborns may account for the 
lower adiponectin levels. All these finding place the LGA newborns in a risc group for metabolic 
syndrome, type 2 DM and cardiovascuar diseases.  
Not only macrosomic babies, also AGA newborns of GDM mothers have disturbed lipid profile 
compared with newborns of healthy mothers, HDL cholesterol was significantly lower and LDL 
cholesterol significantly higher. These finding suggest that not only LGA newborns but also 
AGA newborns are at increased risk for obesity related disorders 
In our knowledge, there is no cross sectional study that have examine correlation of maternal 
adiponectin  with HDL cholesterol at birth in LGA newborns born form mother with and without 
gestational diabetes, but our study failed to show any difference. 
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7  CONCLUSIONS 
 
The GDM is a condition that can impact on the short-term and long term health of both the 
mother and her baby. Adipokines secreted by adipose tissue are required for a number of 
physiological and metabolic processes. Despite the potential importance of these agents as 
mediators of metabolic disorders still it is little known about their implication in GDM and 
macrosomia. 
Current temporal trends are showing increase incidence of gestational diabetes and increasing 
in LGA births. Hypoadiponectinemia in women with increased BMI is associated with the 
pathogenesis of GDM and macrosomia.  
Hyperinsulinemia and hypoadiponectinemia in macrosomic infants are predisposing factors 
that can contribute in development of obesity related disorder.  
The findings of this study describe an altered metabolic environment for the fetus even in well 
controlled GDM mothers. Decreased adiponectin levels in offspring of GDM regardless of body 
fat mass, confer a substantially increased risk for diabetes and cardiovascular diseases, 
suggesting that adiponectin may even contribute directly to the pathogenesis of these diseases.  
Hyperlipidemia and increased insulin resistance found in offspring of GDM mothers increase the 
risk for both neonatal and childhood complication such as obesity. 
It is of great importance that offspring of gestational diabetic mothers should be prospectively 
evaluated for obesity related diseases and get more understanding in the pathogenesis of 
metabolic syndrome and type 2 DM. 
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8  SAŽETAK (ABSTRACT IN CROATIAN) 
 
Uvod:Povećanje učestalosti Diabetesa u trudnoci I makrosomne djece nosi veliki rizik za 
razvitak bolesti povezane za pretilost kao metabolički sindrom I tip 2 dijabetesa . 
 
Ciljevi: Cilj istraživanja je ispitati uzrok pojačanog fetalnog razvitka( > 90 centile ) kod trudnica 
sa dobrom kontrollom gestacijskog diabetesa. 
Pacijenti i Metode: 37 trudne zene sa GDM i 46 zdravih trudnica kao kontrolna grupa I njihova 
novorođenčad su sudjelovali u istrazivanju. Uzorci krvi uzeti su od majke prije poroda i od 
novorođenih u vrijeme poroda I testirana je koncentracije adiponektina, leptina , insulin , c 
peptida, kolesterola, triglicerida, HDL i LDL kolesterol. 
Nalazi: Majke sa diabetesom u trudnoči imaju značajno veći BMI ( prvotromjesečje ) od 
kontrolne skupine ( 29,6 ± 6,0 vs. 23,3 ± 4,3 , P < 0,0001 ) , a koncentracija adiponektina su 
značajno niže u Majke sa diabetesom u trudnoci u usporedbi sa zdravim kontrolnim ispitanicima 
( 10.871,3 ± 5184,2 vs 13.418,9 ± 5148,6 , P = 0,021 ) .  
U djece majki sa diabetesom koncentracije adiponektina ( 24.469,0 10.478,8 ± vs 45.359,6 ± 
7.592 , P = 0.0017 ) su znatno niže kod LGA djece majki s dijabetesom u usporedbi sa LGA 
djece zdrave kontrolne grupe ; I koncentracija inzulina je značajno viša u AGA ( 11,3 ± 14,1 
vs.4.3 ± 3,2 , P < 0,0001 ) i LGA ( 12,9 ± 6,4 vs 5,8 ± 2,9 , P = 0,035 ) djece majki s diabetesom 
u usporedbi sa AGA i LGA djece zdrave kontrolne grupe. 
 
Zakljucak::Nalazi ovog istraživanja opisuju metabolicke promene koje okružuju plod I kod 
dobro kontroliranog diabetesa u trudnoci . Hiperinzulinemija I hypoadiponectinemia u 
makrosomne dojenčadi su predisponirajući čimbenici koji mogu pridonijeti u razvoju bolesti 
povezane za pretilosti kasnije u životu. 
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9  ABSTRACT 
 
Introduction: Increasing incidence of GDM and LGA births predispose children for obesity 
related diseases, metabolic syndrome and type 2 Diabetes. 
Aims: The aim of the study was to investigate the cause of enhanced fetal growth (>90 centiles)in 
well controlled gestational diabetic pregnancies. 
Subjects and methods: 37 GDM mothers and 46 healthy control subjects and their newborns 
participated in the cross sectional study. Blood samples were taken from mother before delivery 
and from neonates at the time of delivery and tested for concentration of adiponectin, leptin, 
insulin, c peptide, cholesterol, triglycerides, HDL and LDL cholesterol. 
Results: Gestational diabetic mothers had significantly higher BMI (first trimester) than a control 
group (29.6 ±6.0 vs. 23.3 ± 4.3, P<0.0001) and adiponectin concentration were significantly 
lower in gestational diabetic mothers compared with healthy control subjects (10871.3 ± 5184.2 
vs. 13418.9 ± 5148.6, P=0.021).   In offspring of GDM concentration of adiponectin (24469.0 ± 
10478.8 vs. 45359.6 ± 7592, P=0.0017) is significantly lower in LGA newborns of GDM 
mothers compared with LGA newborns of healthy control; and concentration of Insulin is 
significantly higher in AGA (11.3 ±14.1 vs.4.3 ±3.2, P<0.0001) and LGA (12.9 ±6.4 vs. 5.8 ±2.9, 
P=0.035) newborn of GDM mothers compared with AGA and LGA newborns of healthy control. 
Conclusions: The findings of this study describe an altered metabolic environment for the fetus 
even in well controlled GDM mothers. Hyperinsulinemia and hypoadiponectinemia in 
macrosomic infants are predisposing factors that can contribute in development of obesity 
related disorder later in their life. 
 
 
 
 
    
 
40 
 
10  REFERENCES 
1. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 
diabetes. Diabetes Care 2002; 25: 1862-1868. 
2. Barbour LA, McCurdy CE, Hernandez TL, et al., Cellular Mechanism for insulin 
resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007; 
30(2):S112-S119. 
3. Desoye G, Mouzon SHD. The human placenta in gestational diabetes mellitus. 
Diabetes Care 2007; 30(2):S120-S126. 
4. Kirwan JP, Hauguel-De Mouzon S, Lepercq J, et al. TNF α is a predictor of insulin 
resistency in human pregnancy. Diabetes 2002; 51: 2207-2213 
5. Cseh K, Baranyi E, Melczer Z, et al. Plasma adiponectin and pregnancy induced 
insulin resistance. Diabetes Care,  2004; 27:274-275 
6. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue 
derived cytokines: in vivo and in vitro investigations in humans. Am J 
Physiolendocrinol Metabolic. 2003; 285:E527-E533 
7. Lepercq J, Challier J-C, Guerre-Millio M et al. Prenatal leptin production. Evidence 
that fetal adipose tissue produces leptin. J ClinEndocrinolmetabol 2001; 86:2409-
2413  
8. Islami D, Bischof P, Chardonnens D. Possible interactions between leptin, 
gonadotropin-releasing hormone (GnRH-I and II) and human chorionic gonadotropin 
(hCG). Eur J ObstetGynecolReprodBiol 2003; 110: 169-175 
9. LappasM,Permezel M, Rice GE. Leptin and adiponectin stimulate the release of 
proinflammatory cytokines and prostaglandins from human placenta and maternal 
adipose tissue via nuclear factor-kappa B, peroxisomal proliferator-activated 
receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 2005; 146 
(8):3334-3342  
    
 
41 
 
10. Radaelli T, Varastehpour A, Catalano P, Hauguel –de Mouzon S: Gestational diabetes 
induces placental genes for chronic stress and inflammatory pathways. Diabetes 
2003; 52:2951-2958 
11. Retnakaran R,. Connelly P.W, Maguire G., Sermer M. et al. Decreased high 
molecular –weight adiponectin in gestational diabetes, implications for the 
pathophysiology of type 2 diabetes. Diabetic Medicine, 2007; 24:245-252 
12. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 
diabetes mellitus. Lancet,  2003; 361:226-228 
13. Catalano PM, Hoegh M, Minium J, et al. Adipoenctin in human pregnancy: 
implication for regulation of glucose and lipid metabolism. Diabetologia 2006; 
49:1677-1685 
14. Henson MC, Castracane VD. Leptin in pregnancy. An update Biol. Reproduct. 2006; 
74, 218-229 
15. Catalano PM, Kirwan JP, Haugel de Mouzon, s, King J: Gestational diabetes and 
insulin resistance: role in short and long term implications for mother and fetuse. 
Journal de Nutrition 2003; 133: 1674S -1683S. 
16. Jansson T. and Powell TL. Role of the placenta in fetal programming underlying 
mechanism and potential interventional approaches. Clinical Science 2007; 113, 1-13. 
17. Catalano PM, Thomas A, Huston Presley L, Amini SB. Increased fetal adiposity: a 
very sensitive marker of abnormal in utero development. Am J ObstetGynecol 2003; 
189:1698-1704. 
18. Dunger DB, Petry CJ, Ong KK. Genetics of size at birth. Diabetes Care, 2007; 
30:S150-S155. 
19. Mostyn A, Pearce S, Stephenson T, Symonds M.E. Hormonal and Nutritional 
Regulation of Adipose Tissue Mitochondrial Development and function in the 
newborn. ExpClinEndocrinol Diabetes 2004; 112:2-9 
    
 
42 
 
20. Koerner A, Kratzsch J, Kiess W Adipocytokines: leptin-the classical, resistin-the 
controversial, adiponectin-the promising, and more to come Best Practice & Research 
Clinical Endocrinology & Metabolism 2005 Vol. 19, No 4,pp. 525-546 
21. Margetic S, Gazzola C, Pegg GG et al.  Leptin: a review of its peripheral actions and 
interactions. International Journal of Obesity (2002) 26, 1407-1433 
22. Linnemann K, Malek A, Schneider H, et al. Physiological and pathological regulation 
of feto/placental/maternal leptin expression 2001 vol.29, part 2 
23. McMillen IC, Edwards LJ, Duffield J and Muhlhausler BS. Regulation of leptin 
synthesis and secretion before birth: implications for the early programming of adult 
obesity Reproduction 2006; 131, 415-427. 
24. Bolt RJ, van Weissenbruch MM, Lafeber HN, et al.. Glucocorticoids and lung 
development in the fetus and preterm infant. PediatrPulmonol 2001;32:76-91 
25. Yang SW, Kim SY. The relationship of the levels of leptin, insulin like growth factor 
and insulin in cord blood with birth size, ponderal index and gender differences. J 
PediatrEndocrinolMetab 2000;13:289-296 
26. PestovitzOra H and Eugster Erica A . Paediatric Endocrinology „Mechanism, 
Manifestation and Management“, 2004; Lippincot Williams & Wilkins 
27. Plagemann A, Harder T, Janert U, Rake A, Rittel F et al: Malformations of 
hypothalamic nuclei in hyperinsulinaemic offspring of gestational diabetic mother 
rats. Dev Neurosci 1999; 21:58-67 
28. Semple RK, Chatterjee VKK, O'Rahilly S. PPARγ and human metabolic disease. J 
Clin Invest 2006; 116:581-589 
29. Ines M.C.G. Pardo, Bruno Geloneze, Marcos A. Tambascia and Antonio A. Barros-
Fihlo. Hyperadiponectinemia in newborns: Relationship with leptin levels and birth 
weight. Obesity Research  2004; vol 12 no 3 
30. Cortelazzi D, Corbetta S, and Ronzoni S. et al. Maternal and fetalresistin and 
adiponectin concentrations in normal and complicated pregnancies. Clinical 
Endocrynology 2007; 66: 447-453 
    
 
43 
 
31. Lindsay RS, Walker JD, Havel PJ, et al. Adiponectin is present in cord blood but is 
unrelated to birth weight. Diabetes care 2003; 26: 2244-2249 
32. Simmons D,  Breier BH. Fetalovernutrition in Polynesian pregnancies and in 
gestational diabetes may lead to disregullation of the adipoinsular axis in offspring. 
Diabetes Care 2002; 25: 1539-1544 
33. Dyer JS, Rosenfeld CR, Rice J, et al. Insulin Resistance in Hispanic Large for 
Gestational Age Neonates at birth. Journ. Of Clin. Endocry.&Metab 2007; 
92(10):3836-3843 
34. Dabalea D, Pettitt DJ, Hanson RL et al. Birth weight, type 2 diabetes and insulin 
resistance in Pima Indian children and young adults. Diabetes Care 1999; 22:944-950 
35. Boney CM, Verma A, Tucker R, Vohr BR. Metabolic syndrome in childhood: 
association with birth weight, maternal obesity, and gestational diabetes mellitus. 
Pediatrics 2005; 115: 290-296 
36. Catalano PM, Thomas A, Huston-Presley L, et al. Phenotype of infants of mothers 
with gestational diabetes. Diabetes Care; 2007; 30 (2):S156-S160. 
37. Schaefer-Graf UM, Brauer M, Kjos SL, et al. Determinants of fetal growth at 
different periods of pregnancies complicated by gestational diabetes mellitus or 
impaired glucose tolerance. Diabetes care 2003; 26:193-198 
38. Ferrara A. Increasing prevalence of gestational diabetes mellitus. Diabetes Care, 
2007; 30 (2):S141-S146. 
39. Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, prager 
R, Waldhausl W. Increased plasma leptin in gestational diabetes Diabetologia 2001; 
44:164-172 
40. Ategbo J.M, Grissa O, Yessoufou A, etal.Modulation of Adipokines and Cytokines in 
Gestational Diabetes and Macrosomia. The Jour. Of Clin.Endoc.&Metab. 2006; 91 
(10):4137- 4143 
    
 
44 
 
41. Louise K Pirc, Julie A Owens, Caroline A Crowther et al. Mild gestational diabetes in 
pregnancy and the adipoinsular axis in babies born to mothers in the ACHOIS 
randomised controlled trial. BMC Pediatrics 2007; 7:18 
42. Festa A, Shnawa N, Krugluger W, Hopmeier P, Schemthanner G, Haffner SM, 
Relative hypoleptinermia in women with mild gestational diabetes mellitus Diabet 
med 16: 656-662 
43. Martin L,WooJ,DanielsS,GoodmanE&DolanL.The relationships of adiponectin with 
insulin and lipids are strengthened with increasing adiposity.Journal of Clinical 
Endocrinology and Metabolism 2005 90 4255-4259 
44. Matsubara M.Maruoca S &KatayoseS.Decreased plasma adipoenctin concentration in 
women with displipidemia.Journal of Clinical Endocrinology and Metabolism 2002 
87 2764-2769 
45. LihnAS.Pedersen SB &Richelsen B. Adipoenctin: action, rregullation and association 
to insulin sensitivity. Obesity Reviews 2005 6 13-21 
46.  E. Kajantie, T.Hytinnantti, P.Hovi and S. Andersson, Cord plasma adiponectin: a 20 
fold rise between 24 weeks gestation and term, J Clin Endocrinology and Metabolism 
89 (2004),pp.4031-4036 
47. C.Taska, E.Chelaru and D.Sdrobici, Fat cell size- body weight correlation in 
newborn, Endocrinologie 16 (1978), pp. 287-289 
48. International Association of Diabetes And Pregnancy Study Groups Consensus Panel. 
International association of diabetes and pregnancy study groups recommendations 
on the diagnosis and classification of hyperglicemia in pregnancy. Diabetes care 
2010;33:676-82 
49. Kershaw EE&Flier JS. Adiposse tissue as an endocrine organ. J ClinEndocrinolMetab 
2004;89:2548-2556 
 
 
  
    
 
45 
 
11  CURRICULUM  VITAE 
 
Vjosa Mulliqi Kotori was born on October 21, 1966, in Prishtina, Kosovo, where she completed 
primary school and gymnasium. 
Education and professional training (graduation year): 
MD: School of Medicine, University of Prishtina, 1993 
Specialisation in Pediatrics: Kosovo University Clinical Centre (KUCC), 2005 
 
Postgraduate Training: 
CME Postgraduate course (1st category) in the field of Diabetology at Univeristy Clinic 
”VukVrhovac” School of Medicine, University of Zagreb, Croatia, 2007. 
CME postgraduate course on Pediatric Endocrinology and Nephrology in Salzburg , Austria, 
2011 
CME postgraduate course on Endocrinology,  Dubrovnik, 2010 
First ISPAD CME on Diabetes, Varna, Bulgaria, 2011, 2013, 2015. 
 
Publications: 6 papers in peer reviewed journals, 1 paper in “DiabetologiaCroatica”, abstracts 
and international conferences. 
    
 
Languages: Albanian, English and Croatian. 
 
Personal data: married, mother of two children. 
 
